The end of Covid-19 due to vaccines? By when do we have our lives back?

The covid-19 outbreak has had a significant impact on daily life of populations in the last year. Recently three pharmaceutical companies have communicated promising results of their vaccination candidates against Covid-19. Various countries in Europe have implemented vaccination programs or strategies how to set these up. Within the webinar those programs will be assessed utilizing a Covid-19 SEIR model (CovidSIM). The MArS expert team will show you in the webinar:
• Vaccination programs in Europe
• Implication of these programs from a simulation perspective
• An estimation of when the “old” normal might be the “new(set)” normal

The webinar will be held one week before Christmas. The first 24 registrations will receive a German “Gluehwein” as normally available on German Christmas markets.

EU HTA to come?

There is a big debate since years on the potential implementation of a joint HTA system across Europe. Core questions on such a system remains on how such an approach could look like and even more important be implemented. The webinar will summarize the current status of the debate and also suggest a way how such a joint HTA could be implemented in the European Union.

Register now: https://us02web.zoom.us/webinar/register/4715954498495/WN_8WnsBaNyQZKf4BFvtgBP4g

New Webinar on Covid-19 and digitalization on May 28 2020

The covid-19 outbreak has had a significant impact on daily life of populations and health care systems. Due to physical distancing as a core policy, digitalization is a main opportunity also in health care. At the same time the new law for digitalization in health care (DiGA) was made effective In Germany.

The MArS Covid-19 task force will show you in this webinar:

  • How digitalization has changed the health care system
  • The different pathways for digitalization solutions to the German market

Register now: Webinars

Video available – MArS webinar – Covid-19 cost on Germany

On Thursday, April 23 2020, MArS offered the webinar “How many billion of Euros does the fight against the Covid-19-virus cost the healthcare system? A health economic modelling analysis for Germany”.

The presentation as a video is now available:

MArS has extensive experience in health economic modelling an support you in your endeavors.

Enjoy the video and stay healthy!

MArS webinar slides on cost of Covid-19 available

On Thursday, April 23 2020, MArS offered the webinar “How many billion of Euros does the fight against the Covid-19-virus cost the healthcare system? A health economic modelling analysis for Germany”.

The presented slides are now available on our website MArS – Stefan Walzer – Webinar – Covid-19 impact health economics Germany

MArS has extensive experience in health economic modelling an support you in your endeavors.

Stay healthy!

Price negotiation article published – link MArS negotiation boot camp

Price negotiation strategy is most of the times also linked to the available evidence and the potential bet on future data. Gladwell et al. have just published a nice simulation approach with the example in the UK which can also be utilized in the D-A-CH context. For the German AMNOG that approach is also relevant for orphan drugs earlier in the process also with the G-BA and for any pharmaceutical within the price negotiations with the GKV-SV.

The article is available in Value in Health.

MArS has long-lasting experience in (price) negotiations in the D-A-CH regions. We have also developed an internal and successful negotiation boot camp utilizing virtual reality. Contact us for a live demonstration.

MArS is now a proud member of the Head Association of Digital Health Care in Germany!!

The Head Association of Digital Health Care (SVDGV) has just been established in 2019 also driven by the new regulations on reimbursement for medical apps. MArS is a member and joined the working groups on reimbursement and evidence.

MArS has a vast majority of experience in the German reimbursement landscape, submissions and price negotiations and will be able to also transfer that into the new field for reimbursement of medical apps. Contact us.

New government in Austria – impact on the medical industry and market access?

What does this mean for the pharmaceutical and medical device industry? MArS has created a country profile update Austria – a summary is available below – the full report is available on request.

Ultimately: Given the structural changes in the overall health care system in Austria it is not expected that there will be major changes within the frame and decision criteria by the Hauptverband and hence market access.

MArS has vast experience in submissions, pricing and negotiations in Austria. Contact us!!